Erythromycin is an antibiotic, which is used to treat certain kind of
bacterial infections. Erythromycin topical preparations are largely
used on the skin to help control acne. The antibiotic is also used in
combination with other medicines and are applied topically or taken
orally for treating the infections. The common side effects of
erythromycin include nausea, loss of appetite, diarrhea, and
abdominal pain. Erythromycin prevents bacterial cells from growing
and multiplying by interfering with their ability to make proteins,
while not affecting human cells. It is widely used to treat chest
infections such as pneumonia, skin problems such as acne and rosacea,
dental abscesses, and sexually transmitted infections.
Ask
For Sample Copy at
https://www.coherentmarketinsights.com/insight/request-sample/1780
Erythromycin Market Dynamics
Pharmaceutical manufacturers are focused on increasing access to
affordable medications to provide novel options for patients and
pharmacists, thereby addressing the limited availability of
erythromycin tablets, which in turn is expected to augment market
growth. For instance, in March, 2018, Amneal Pharmaceuticals received
FDA approval for Erythromycin Tablets USP, 250 mg and 500 mg
strengths. The erythromycin product is a therapeutic equivalent for
the reference listed drug (RLD) erythromycin tablets from Arbor
Pharmaceuticals and is the only other immediate release oral tablet
available. Moreover, in September 2016, ANI Pharmaceuticals, Inc.
launched Erythromycin Ethylsuccinate for oral suspension 200mg/5mL
indicated as a treatment for various infections including upper and
lower respiratory, skin and soft tissue, genitourinary, Legionnaires
disease, pertussis, and others.
Erythromycin Market - Regional Dynamics
Regional segmentation of the global erythromycin market by Coherent
Market Insights comprises North America, Latin America, Europe, Asia
Pacific, Middle East, and Africa. North America erythromycin market
is expected to hold a dominant position over the forecast period,
owing to rising number of regulatory approvals of drugs by regulatory
agencies to address the unmet medical needs of the patients and
increasing prevalence of skin and soft tissue infections. For
instance, in November, 2016, Rising Pharmaceuticals, Inc.—a
subsidiary of Aceto Corporation—launched Erythromycin and Benzoyl
Peroxide Topical Gel USP, 3-5% an FDA-approved generic version of
Valeant International’s Benzamycin Gel, 3-5%. According to the
Division of Infectious Diseases, Los Angeles BioMedical Research
Center, 2015, skin and soft tissue infections (SSTIs) are a common
reason to seek medical care in the U.S. as they can lead to
complications with significant morbidity, including hospitalization,
surgical procedures, or death.
Erythromycin Market- Competitive Analysis
Key players operating in the global erythromycin market include Ani
Pharmaceuticals, Akorn, Inc., Aceto Corporation, Genesis
Pharmaceuticals, Teligent, Inc., Abbvie, Inc., Abbott Laboratories,
Pfizer, Inc., Sanofi-Aventis, and Allergan, Plc.
Erythromycin
Market Taxonomy:
On
the basis of formulation, the global erythromycin market is segmented
into:
-
Gel
-
Tablet
-
Topical Solution
-
Ointment
-
Others
On
the basis of therapeutic indications, the global erythromycin market
is segmented into:
-
Respiratory Tract Infections
-
Eye Infections
-
Ear Infections
-
Skin and Soft Tissue Infections
-
Gastro-intestinal Infections
-
Others
On
the basis of distribution channel, the global erythromycin market is
segmented into:
-
Hospital Pharmacies
-
Retail Pharmacies
-
Online Pharmacies
On
the basis of region, the global erythromycin market is segmented
into:
-
North America
-
Latin America
-
Europe
-
Asia Pacific
-
Middle East
-
Africa
Browse
Full Report at
https://www.coherentmarketinsights.com/ongoing-insight/erythromycin-market-1780
Also,
Coherent Market Insights has a proprietary database of pipeline
biologics and biosimilars, called PHASE-XS. This database provides
analytical data in addition to the clinical information of ongoing
trials for biologics and biosimilars. An amalgamation of more than 30
parameters, PHASE-XS helps biotechnology and pharmaceutical companies
to analyze the market trend, competition, and market potential. For
more information or to access this database, kindly click on the
below link or contact at sales@coherentmarketinsights.com
About
Coherent Market Insights:
Coherent
Market Insights is a prominent market research and consulting firm
offering action-ready syndicated research reports, custom market
analysis, consulting services, and competitive analysis through
various recommendations related to emerging market trends,
technologies, and potential absolute dollar opportunity.
Contact
Us:
Mr.
Shah
Coherent
Market Insights
1001
4th Ave,
#3200
Seattle,
WA 98154
Tel:
+1-206-701-6702
No comments:
Post a Comment